CONTEXT AND OBJECTIVE: Adult-onset idiopathic hypogonadotropic hypogonadism (AHH) is a rare disorder characterized by an isolated failure of gonadotropin secretion occurring after an otherwise normal sexual maturation in men. This study aims to examine the etiology and long-term natural history of this disorder. DESIGN AND SETTING: Long-term follow up, including detailed clinical, biochemical, and genetic examinations, were performed and compared with those at diagnosis. PATIENTS: Patients included 10 men with AHH [serum testosterone (T) <125 ng/dl]. INTERVENTIONS: Overnight neuroendocrine studies, semen fluid analyses, and genetic screening were performed (KAL1, FGFR1, PROK2, PROKR2, NELF, TAC3, TACR3, and GNRH1) over a decade of longitudinal follow up. RESULTS: Follow-up evaluations were conducted 10.6 +/- 5.9 yr after initial studies and revealed that the clinical characteristics and seminal fluid analyses of AHH men (body mass index, 28.8 +/- 4.1 vs. 27.0 +/- 4.3 kg/m(2); testicular volume, 18 +/- 6 vs. 19 +/- 6 ml) do not change over a decade with no spontaneous reversals. Several men exhibited some variability in their endogenous GnRH-induced LH secretory patterns, including emergence of endogenous pulsatility in three individuals. However, all remained hypogonadal (T < or =130 ng/dl). A single heterozygous DNA sequence change in PROKR2 (V317L) was identified, although this rare sequence variant did not prove to be functionally abnormal in vitro. Seven days of pulsatile GnRH therapy in this subject nearly normalized his serum T, supporting that the site of the defect is hypothalamic and not pituitary. CONCLUSIONS: 1) AHH in men appears to be a long-lasting condition. 2) Although minor changes in the abnormal pattern of endogenous GnRH-induced LH secretion occurred in some AHH patients, all remained frankly hypogonadal.
CONTEXT AND OBJECTIVE: Adult-onset idiopathic hypogonadotropic hypogonadism (AHH) is a rare disorder characterized by an isolated failure of gonadotropin secretion occurring after an otherwise normal sexual maturation in men. This study aims to examine the etiology and long-term natural history of this disorder. DESIGN AND SETTING: Long-term follow up, including detailed clinical, biochemical, and genetic examinations, were performed and compared with those at diagnosis. PATIENTS: Patients included 10 men with AHH [serum testosterone (T) <125 ng/dl]. INTERVENTIONS: Overnight neuroendocrine studies, semen fluid analyses, and genetic screening were performed (KAL1, FGFR1, PROK2, PROKR2, NELF, TAC3, TACR3, and GNRH1) over a decade of longitudinal follow up. RESULTS: Follow-up evaluations were conducted 10.6 +/- 5.9 yr after initial studies and revealed that the clinical characteristics and seminal fluid analyses of AHHmen (body mass index, 28.8 +/- 4.1 vs. 27.0 +/- 4.3 kg/m(2); testicular volume, 18 +/- 6 vs. 19 +/- 6 ml) do not change over a decade with no spontaneous reversals. Several men exhibited some variability in their endogenous GnRH-induced LH secretory patterns, including emergence of endogenous pulsatility in three individuals. However, all remained hypogonadal (T < or =130 ng/dl). A single heterozygous DNA sequence change in PROKR2 (V317L) was identified, although this rare sequence variant did not prove to be functionally abnormal in vitro. Seven days of pulsatile GnRH therapy in this subject nearly normalized his serum T, supporting that the site of the defect is hypothalamic and not pituitary. CONCLUSIONS: 1) AHH in men appears to be a long-lasting condition. 2) Although minor changes in the abnormal pattern of endogenous GnRH-induced LH secretion occurred in some AHHpatients, all remained frankly hypogonadal.
Authors: Yee-Ming Chan; Sarabeth Broder-Fingert; Sophia Paraschos; Risto Lapatto; Margaret Au; Virginia Hughes; Suzy D C Bianco; Le Min; Lacey Plummer; Felecia Cerrato; Adelaide De Guillebon; I-Hsuan Wu; Fazal Wahab; Andrew Dwyer; Susan Kirsch; Richard Quinton; Timothy Cheetham; Metin Ozata; Svetlana Ten; Jean-Pierre Chanoine; Nelly Pitteloud; Kathryn A Martin; Raphael Schiffmann; Hetty J Van der Kamp; Shahla Nader; Janet E Hall; Ursula B Kaiser; Stephanie B Seminara Journal: J Clin Endocrinol Metab Date: 2011-08-31 Impact factor: 5.958
Authors: Yee-Ming Chan; James P Butler; Nancy E Pinnell; François P Pralong; William F Crowley; Chen Ren; Kenneth K Chan; Stephanie B Seminara Journal: J Clin Endocrinol Metab Date: 2011-04-06 Impact factor: 5.958
Authors: Valerie F Sidhoum; Yee-Ming Chan; Margaret F Lippincott; Ravikumar Balasubramanian; Richard Quinton; Lacey Plummer; Andrew Dwyer; Nelly Pitteloud; Frances J Hayes; Janet E Hall; Kathryn A Martin; Paul A Boepple; Stephanie B Seminara Journal: J Clin Endocrinol Metab Date: 2013-01-01 Impact factor: 5.958
Authors: Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica Journal: Rev Endocr Metab Disord Date: 2021-02-22 Impact factor: 6.514